CTOs on the Move

Home Advantage

www.home-adv.com

 
Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.home-adv.com
  • 13800 Coppermine Rd Ste 300
    Herndon, VA USA 20171
  • Phone: 800.297.2180

Executives

Name Title Contact Details

Similar Companies

EMD Chemicals

EMD Chemicals Inc. is a Gibbstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspect Biosystems

Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company`s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine.

Perlegen Sciences

Perlegen Sciences, Inc. is a Newark, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bedrocan

Bedrocan is an experienced producer of pharmaceutical-grade medicinal cannabis with over 13 years growing expertise in global markets. We provide patients and healthcare professionals with safe, effective and consistent medicine for the appropriate management of diagnosed health conditions. Our strains of pharmaceutical-grade cannabis are used by thousands of patients in seven countries, including Canada. We provide three fully standardized products, and as a result, our standardized strains are the choice for researchers and academics who study the medical effects of cannabis.

NextCure

NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.